OncoMatch/Head & Neck Cancer (HNSCC)/EGFR
Head & Neck Cancer (HNSCC)EGFR Clinical Trials
EGFR overexpression is near-universal in HNSCC, and cetuximab — an anti-EGFR monoclonal antibody — is an approved treatment option in recurrent/metastatic disease and as part of concurrent chemoradiation. EGFR gene amplification occurs in ~10–15% of cases. Trials investigate novel EGFR-directed ADCs (ABT-165), bispecific antibodies (EGFR × MET, EGFR × PD-L1), and cetuximab combinations with checkpoint immunotherapy for EGFR-amplified or -overexpressing HNSCC.
Top recruiting EGFR Head & Neck Cancer (HNSCC) trials
Ranked by phase and US site count. See all 12 trials matched to your profile →
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
Fudan University
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
CJ Bioscience, Inc.
Browse other molecular targets with active Head & Neck Cancer (HNSCC) trials.